Trial Profile
Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life. Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2014
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 10 Mar 2014 New trial record